New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2014
07:46 EDTSRPTSarepta price target raised to $35 from $22 at RW Baird
Baird raised its price target on Sarepta following its update on pulmonary data that provides incremental evidence of efficacy of its 6MWT results from last month. The firm expects the next catalyst to be clarity on its pivotal trial design. Shares are Outperform rated.
News For SRPT From The Last 14 Days
Check below for free stories on SRPT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 21, 2014
09:01 EDTSRPTSarepta enters into partnership with Flagship Biosciences
Sarepta Therapeutics and Flagship Biosciences announced a multi-year, multi-product partnership for the development of automated quantitative endpoint measurements in muscular dystrophy to support the advancement of Sarepta’s Duchenne muscular dystrophy drug pipeline, including its lead candidate, eteplirsen. This newly established collaboration with Flagship demonstrates Sarepta’s commitment to enhancing the objective measurement of dystrophin in tissue samples for its growing pipeline of RNA-based therapeutics to treat DMD.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use